Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biosource International -- Ignore unavailable to you. Want to Upgrade?

To: Joe Dancy who wrote (513)	7/7/1998 3:08:00 PM
From: tom pope	Read Replies (2) \| Respond to of 696

Joe, when do they report 2Q earnings? Do you know offhand what is the status of analysts' estimates and whether there have been any recent upgrades. The revenue line is key, so your report is very encouraging when it says that revenue is expected to grow strongly. Would you agree that it is the flattish revenue of the past year that has impeded the stock price? Tom

To: Joe Dancy who wrote (513)	7/8/1998 2:10:00 AM
From: geoffrey Wren	Read Replies (1) \| Respond to of 696

Re: "AIDS, cancer, and related research would drive growth of this sector of the biotech market upward at a 20% annual rate for the foreseeable future." Presumably a reasonable way to look at it. But will the development of new drugs through the new better founded techniques (monoclonal antibodies, tumor starvation, etc.) use more of what BIOI sells or not? I have no idea myself. But assuming the demand for treatments equals dollars spent on research which benefits BIOI, then consider sooner or later heaps of money will be thrown at Hepatitis C research. It should have funding now at least with a parity with HIV. 1m HIV carriers in the US, 4m Hepatitis C carriers. Pretty deadly disease, apparent latency of some 10-15 years. BIOI looks like a good company in a growth field. I own a little. What makes me hesitate a little is I followed a company called ICN (something) that traded on AMEX, a small company related to ICN the drug company for a few years some long time ago (some 8 years ago or so). I believe it was like BIOI in selling raw materials to medical labs. It never went anywhere. I think the risk is that if you are just selling a commodity, price competition is tough. My first post on this board. Geoff Wren